174 related articles for article (PubMed ID: 17367119)
1. Mechanism of drug resistance due to N88S in CRF01_AE HIV-1 protease, analyzed by molecular dynamics simulations.
Ode H; Matsuyama S; Hata M; Hoshino T; Kakizawa J; Sugiura W
J Med Chem; 2007 Apr; 50(8):1768-77. PubMed ID: 17367119
[TBL] [Abstract][Full Text] [Related]
2. Resistant mechanism against nelfinavir of human immunodeficiency virus type 1 proteases.
Ode H; Ota M; Neya S; Hata M; Sugiura W; Hoshino T
J Phys Chem B; 2005 Jan; 109(1):565-74. PubMed ID: 16851048
[TBL] [Abstract][Full Text] [Related]
3. Understanding the HIV-1 protease nelfinavir resistance mutation D30N in subtypes B and C through molecular dynamics simulations.
Soares RO; Batista PR; Costa MG; Dardenne LE; Pascutti PG; Soares MA
J Mol Graph Model; 2010 Sep; 29(2):137-47. PubMed ID: 20541446
[TBL] [Abstract][Full Text] [Related]
4. Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants.
Kozísek M; Bray J; Rezácová P; Sasková K; Brynda J; Pokorná J; Mammano F; Rulísek L; Konvalinka J
J Mol Biol; 2007 Dec; 374(4):1005-16. PubMed ID: 17977555
[TBL] [Abstract][Full Text] [Related]
5. Drug Resistance Mechanism of L10F, L10F/N88S and L90M mutations in CRF01_AE HIV-1 protease: Molecular dynamics simulations and binding free energy calculations.
Vasavi CS; Tamizhselvi R; Munusami P
J Mol Graph Model; 2017 Aug; 75():390-402. PubMed ID: 28645089
[TBL] [Abstract][Full Text] [Related]
6. The effect of clade-specific sequence polymorphisms on HIV-1 protease activity and inhibitor resistance pathways.
Bandaranayake RM; Kolli M; King NM; Nalivaika EA; Heroux A; Kakizawa J; Sugiura W; Schiffer CA
J Virol; 2010 Oct; 84(19):9995-10003. PubMed ID: 20660190
[TBL] [Abstract][Full Text] [Related]
7. Resistance mechanism revealed by crystal structures of unliganded nelfinavir-resistant HIV-1 protease non-active site mutants N88D and N88S.
Bihani SC; Das A; Prashar V; Ferrer JL; Hosur MV
Biochem Biophys Res Commun; 2009 Nov; 389(2):295-300. PubMed ID: 19720046
[TBL] [Abstract][Full Text] [Related]
8. Computational simulations of HIV-1 proteases--multi-drug resistance due to nonactive site mutation L90M.
Ode H; Neya S; Hata M; Sugiura W; Hoshino T
J Am Chem Soc; 2006 Jun; 128(24):7887-95. PubMed ID: 16771502
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms and drug resistance analysis of HIV-1 CRF01_AE strains circulating in Fujian Province, China.
Liu J; Yue J; Wu S; Yan Y
Arch Virol; 2007; 152(10):1799-805. PubMed ID: 17619115
[TBL] [Abstract][Full Text] [Related]
10. Computational characterization of structural role of the non-active site mutation M36I of human immunodeficiency virus type 1 protease.
Ode H; Matsuyama S; Hata M; Neya S; Kakizawa J; Sugiura W; Hoshino T
J Mol Biol; 2007 Jul; 370(3):598-607. PubMed ID: 17524421
[TBL] [Abstract][Full Text] [Related]
11. Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N.
Clemente JC; Hemrajani R; Blum LE; Goodenow MM; Dunn BM
Biochemistry; 2003 Dec; 42(51):15029-35. PubMed ID: 14690411
[TBL] [Abstract][Full Text] [Related]
12. Structural Basis of Why Nelfinavir-Resistant D30N Mutant of HIV-1 Protease Remains Susceptible to Saquinavir.
Prashar V; Bihani SC; Ferrer JL; Hosur MV
Chem Biol Drug Des; 2015 Sep; 86(3):302-8. PubMed ID: 25487655
[TBL] [Abstract][Full Text] [Related]
13. Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease.
Gupta A; Jamal S; Goyal S; Jain R; Wahi D; Grover A
BMC Bioinformatics; 2015; 16 Suppl 19(Suppl 19):S10. PubMed ID: 26695135
[TBL] [Abstract][Full Text] [Related]
14. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
Garriga C; Pérez-Elías MJ; Delgado R; Ruiz L; Nájera R; Pumarola T; Alonso-Socas Mdel M; García-Bujalance S; Menéndez-Arias L;
J Med Virol; 2007 Nov; 79(11):1617-28. PubMed ID: 17854027
[TBL] [Abstract][Full Text] [Related]
15. Evolutionary analysis of HIV-1 protease inhibitors: Methods for design of inhibitors that evade resistance.
Stoffler D; Sanner MF; Morris GM; Olson AJ; Goodsell DS
Proteins; 2002 Jul; 48(1):63-74. PubMed ID: 12012338
[TBL] [Abstract][Full Text] [Related]
16. Molecular dynamics simulations applied to the study of subtypes of HIV-1 protease common to Brazil, Africa, and Asia.
Batista PR; Wilter A; Durham EH; Pascutti PG
Cell Biochem Biophys; 2006; 44(3):395-404. PubMed ID: 16679526
[TBL] [Abstract][Full Text] [Related]
17. Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir.
Grossman Z; Paxinos EE; Averbuch D; Maayan S; Parkin NT; Engelhard D; Lorber M; Istomin V; Shaked Y; Mendelson E; Ram D; Petropoulos CJ; Schapiro JM
Antimicrob Agents Chemother; 2004 Jun; 48(6):2159-65. PubMed ID: 15155216
[TBL] [Abstract][Full Text] [Related]
18. Drug design: new inhibitors for HIV-1 protease based on Nelfinavir as lead.
Perez MA; Fernandes PA; Ramos MJ
J Mol Graph Model; 2007 Oct; 26(3):634-42. PubMed ID: 17459746
[TBL] [Abstract][Full Text] [Related]
19. PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study.
Dandache S; Coburn CA; Oliveira M; Allison TJ; Holloway MK; Wu JJ; Stranix BR; Panchal C; Wainberg MA; Vacca JP
J Med Virol; 2008 Dec; 80(12):2053-63. PubMed ID: 19040279
[TBL] [Abstract][Full Text] [Related]
20. Within-host co-evolution of Gag P453L and protease D30N/N88D demonstrates virological advantage in a highly protease inhibitor-exposed HIV-1 case.
Shibata J; Sugiura W; Ode H; Iwatani Y; Sato H; Tsang H; Matsuda M; Hasegawa N; Ren F; Tanaka H
Antiviral Res; 2011 Apr; 90(1):33-41. PubMed ID: 21338625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
